Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: paroxetine CR Clear all

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Paroxetine CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 46
States / cities: Little Rock, Arkansas • Anaheim, California • Beverly Hills, California + 40 more

Conditions: Fibromyalgia Syndrome
Interventions: Paroxetine CR, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Menopause
Interventions: Paroxetine, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hot Flashes
Interventions: Paroxetine controlled-release, Conjugated equine estrogen; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: paroxetine CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 3
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Irritable Bowel Syndrome
Interventions: Paroxetine CR, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Depression
Interventions: Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT); Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Posttraumatic Stress Disorder
Interventions: Paroxetine, Prolonged Exposure Therapy; Drug · Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression, Suicidal Ideation
Interventions: Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Stress Disorders, Post-Traumatic
Interventions: Prolonged Exposure Therapy, Paroxetine-CR; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Paxil-CR; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Depression
Interventions: Paroxetine, Bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Anxiety Disorder
Interventions: Continued Paroxetine CR, Quetiapine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Parkinson Disease, Depression
Interventions: paroxetine, Nortriptyline, placebo; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 35 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Major Depressive Disorder
Interventions: mixed salts amphetamine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anxiety Disorders
Interventions: No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depressive Disorder
Interventions: Paxil CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Buffalo, New York • Tacoma, Washington

Conditions: Stress Disorders, Post-Traumatic
Interventions: Cognitive-behavioral therapy and paroxetine-CR; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Durham, North Carolina + 1 more

Conditions: PTSD
Interventions: Paroxetine CR; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Search by objective public record fields.

Depression Study In Elderly Patients

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome

Study of Paxil Use in Menopausal Women

Study of PET Scans and Serotonin in Hot Flashes Treatment

Major Depressive Disorder Study In Adults

Treatment of Obsessive Compulsive Disorder in Children

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy

Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

Treatment of Depression in Parkinson's Disease Trial

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

PAXIL CR Bioequivalence Study

Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)